RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Total liabilities

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndTotal liabilities (Million USD)YoY (%)
Dec 31, 20248,406+18.27%
Dec 31, 20237,107+8.50%
Dec 31, 20226,551-1.73%
Dec 31, 20216,666+8.60%
Dec 31, 20206,138+65.20%
Dec 31, 20193,716+24.80%
Dec 31, 20182,977+13.62%
Dec 31, 20172,620+3.80%
Dec 31, 20162,524+29.16%
Dec 31, 20151,954+46.99%
Dec 31, 20141,330+33.09%
Dec 31, 2013999+19.62%
Dec 31, 2012835-0.33%
Dec 31, 2011838+49.19%
Dec 31, 2010562

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)